MS RESEARCH AUSTRALIA TRIALS
Although there has been quite a bit of research into the contribution of genes to the risk of […]
Myelin oligodendrocyte glycoprotein (MOG) antibody is associated with many demyelinating conditions, but it has not be characterised in-depth. […]
A large international study led by an Australian researcher has identified risk factors that may contribute to conversion to secondary progressive MS.
Secondary progressive MS, a form of MS that can follow on from relapsing remitting MS, currently has no […]
The PBAC has recommended the PBS criteria for two existing MS medications, Gilenya and Tysabri, be broadened which would allow reimbursement for young people with MS.
Up to 65% of people with MS report difficulties with thinking and memory, but many cognitive tests cause […]